Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of oral PIPE-791 in idiopathic pulmonary fibrosis
MOH_2026-03-12_015713Phase 2Not yet recruiting
- Sponsor
- Contineum Therapeutics
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Contineum Therapeutics. Primary endpoint: Change in forced vital capacity from baseline. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
PIPE-791
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on MOH_2026-03-12_015713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-03-12_015713.